Literature DB >> 20927054

Neuro-oncology: Therapeutic benefits of reirradiation for recurrent brain tumors.

Ian F Pollack.   

Abstract

Entities:  

Mesh:

Year:  2010        PMID: 20927054     DOI: 10.1038/nrneurol.2010.144

Source DB:  PubMed          Journal:  Nat Rev Neurol        ISSN: 1759-4758            Impact factor:   42.937


× No keyword cloud information.
  10 in total

1.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group.

Authors:  Patrick Y Wen; David R Macdonald; David A Reardon; Timothy F Cloughesy; A Gregory Sorensen; Evanthia Galanis; John Degroot; Wolfgang Wick; Mark R Gilbert; Andrew B Lassman; Christina Tsien; Tom Mikkelsen; Eric T Wong; Marc C Chamberlain; Roger Stupp; Kathleen R Lamborn; Michael A Vogelbaum; Martin J van den Bent; Susan M Chang
Journal:  J Clin Oncol       Date:  2010-03-15       Impact factor: 44.544

2.  Survival benefit of stereotactic radiosurgery for patients with malignant glial neoplasms.

Authors:  D Kondziolka; J C Flickinger; D J Bissonette; M Bozik; L D Lunsford
Journal:  Neurosurgery       Date:  1997-10       Impact factor: 4.654

3.  Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent high-grade gliomas.

Authors:  Shannon E Fogh; David W Andrews; Jon Glass; Walter Curran; Charles Glass; Colin Champ; James J Evans; Terry Hyslop; Edward Pequignot; Beverly Downes; Eileen Comber; Mitchell Maltenfort; Adam P Dicker; Maria Werner-Wasik
Journal:  J Clin Oncol       Date:  2010-05-17       Impact factor: 44.544

4.  Gamma knife for glioma: selection factors and survival.

Authors:  D A Larson; P H Gutin; M McDermott; K Lamborn; P K Sneed; W M Wara; J C Flickinger; D Kondziolka; L D Lunsford; W R Hudgins; G M Friehs; K Haselsberger; K Leber; G Pendl; S S Chung; R J Coffey; R Dinapoli; E G Shaw; S Vermeulen; R F Young; M Hirato; H K Inoue; C Ohye; T Shibazaki
Journal:  Int J Radiat Oncol Biol Phys       Date:  1996-12-01       Impact factor: 7.038

5.  Brachytherapy for recurrent malignant astrocytoma.

Authors:  M Bernstein; N Laperriere; J Glen; P Leung; C Thomason; A E Landon
Journal:  Int J Radiat Oncol Biol Phys       Date:  1994-12-01       Impact factor: 7.038

6.  GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis.

Authors:  Arash J Gabayan; Sylvan B Green; Abhay Sanan; Joseph Jenrette; Christopher Schultz; Michael Papagikos; Stephen P Tatter; Ashish Patel; Pradip Amin; Robert Lustig; Kenneth T Bastin; Gordon Watson; Stuart Burri; Baldassarre Stea
Journal:  Neurosurgery       Date:  2006-04       Impact factor: 4.654

7.  Hypofractionated stereotactic radiotherapy in the management of recurrent glioma.

Authors:  S F Shepherd; R W Laing; V P Cosgrove; A P Warrington; F Hines; S E Ashley; M Brada
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

8.  Reirradiation of recurrent high-grade gliomas using amino acid PET (SPECT)/CT/MRI image fusion to determine gross tumor volume for stereotactic fractionated radiotherapy.

Authors:  Anca L Grosu; Wolfgang A Weber; Martina Franz; Sibylle Stärk; Morand Piert; Reinhard Thamm; Hartmut Gumprecht; Markus Schwaiger; Michael Molls; Carsten Nieder
Journal:  Int J Radiat Oncol Biol Phys       Date:  2005-10-01       Impact factor: 7.038

9.  Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution.

Authors:  Stephanie E Combs; Christoph Thilmann; Lutz Edler; Jürgen Debus; Daniela Schulz-Ertner
Journal:  J Clin Oncol       Date:  2005-12-01       Impact factor: 44.544

10.  Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy?

Authors:  Emmanouil Fokas; Ulrich Wacker; Markus W Gross; Martin Henzel; Elitsa Encheva; Rita Engenhart-Cabillic
Journal:  Strahlenther Onkol       Date:  2009-04-16       Impact factor: 3.621

  10 in total
  8 in total

1.  microRNA-200a downregulation in human glioma leads to Gαi1 over-expression, Akt activation, and cell proliferation.

Authors:  Yuan-Yuan Liu; Min-Bin Chen; Long Cheng; Zhi-Qing Zhang; Zheng-Quan Yu; Qin Jiang; Gang Chen; Cong Cao
Journal:  Oncogene       Date:  2018-03-09       Impact factor: 9.867

2.  ROS-p53-cyclophilin-D signaling mediates salinomycin-induced glioma cell necrosis.

Authors:  Li-sen Qin; Pi-feng Jia; Zhi-qing Zhang; Shi-ming Zhang
Journal:  J Exp Clin Cancer Res       Date:  2015-05-30

3.  microRNA-153 Targets mTORC2 Component Rictor to Inhibit Glioma Cells.

Authors:  Yan Cui; Jizong Zhao; Lei Yi; Yugang Jiang
Journal:  PLoS One       Date:  2016-06-13       Impact factor: 3.240

4.  miR-92a-3p Exerts Various Effects in Glioma and Glioma Stem-Like Cells Specifically Targeting CDH1/β-Catenin and Notch-1/Akt Signaling Pathways.

Authors:  Hang Song; Yao Zhang; Na Liu; Sheng Zhao; Yan Kong; Liudi Yuan
Journal:  Int J Mol Sci       Date:  2016-10-27       Impact factor: 5.923

5.  Gαi3 nuclear translocation causes irradiation resistance in human glioma cells.

Authors:  Shang Cai; Ya Li; Jin-Yu Bai; Zhi-Qing Zhang; Yin Wang; Yin-Biao Qiao; Xiao-Zhong Zhou; Bo Yang; Ye Tian; Cong Cao
Journal:  Oncotarget       Date:  2017-05-23

6.  Gab3 overexpression in human glioma mediates Akt activation and tumor cell proliferation.

Authors:  Pifeng Jia; Feng Li; Weiting Gu; Weifeng Zhang; Yu Cai
Journal:  PLoS One       Date:  2017-03-14       Impact factor: 3.240

7.  Overexpression of MicroRNA-216a Suppresses Proliferation, Migration, and Invasion of Glioma Cells by Targeting Leucine-Rich Repeat-Containing G Protein-Coupled Receptor 5.

Authors:  Junfeng Zhang; Kun Xu; Lili Shi; Li Zhang; Zhaohua Zhao; Hao Xu; Fei Liang; Hongbo Li; Yan Zhao; Xi Xu; Yingfang Tian
Journal:  Oncol Res       Date:  2017-03-02       Impact factor: 5.574

8.  Ninjurin2 overexpression promotes glioma cell growth.

Authors:  Li-Na Zhou; Ping Li; Shang Cai; Gang Li; Fang Liu
Journal:  Aging (Albany NY)       Date:  2019-12-02       Impact factor: 5.682

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.